Program by Day

Tuesday, September 5, 2017 

1:00 p.m. – 5:30 p.m.
Complimentary Pre-Conference Workshop: Antibiotic Development Bootcamp – Sponsored by CARB-XED, GARDP, ASM, and ESCMID
(Bootcamp series continues Thursday with Bootcamp #3 Clinical Microbiology for a Development Program session) 

1:00 p.m. – 1:05 p.m.
Introduction to the afternoon
John H. Rex, CARB-XED

1:05 p.m. – 2:55 p.m.
Bootcamp #1: Decisions, Decisions: What Makes a Good Hit? A Good Lead? Why Do You Write a TPP? How Do You Write a TPP?
Moderator: Lynn Silver, LL Silver consulting, LLC

  • Lynn Silver, LL Silver Consulting, LLC
  • Tom Dougherty, Harvard Medical School
  • John Tomayko, Infectious Diseases Consultant
  • Sherman T. Waddell, Prokaryotics, Inc.

2:55 p.m. – 3:10 p.m. 
Coffee Break 

3:10 p.m. – 5:00 p.m.
Bootcamp #2: How Does a Molecule Become a Physical Medicine to be Given to a Human: The Importance of Chemistry, Manufacturing, and Controls 
Moderator: Tim Keutzer, Spero Therapeutics

  • Tim Keutzer, Spero Therapeutics
  • Evan Hecker, Spero Therapeutics
  • Mike Young, Tedor Pharma Inc
  • Andrew Barlow, Syner-G Pharma Consulting

5:00 p.m. – 5:30 p.m. 
GARDP Antibiotic Memory Recovery Portal 
Moderator & Discussant: Giovanni Salerno, GARDP

5:30 p.m. – 7:30 p.m.
Wine and Cheese Reception

Back to Tuesday's program 

Wednesday, September 6, 2017 

7:30 a.m. – 8:00 a.m.
Light Breakfast

8:00 a.m. – 8:15 a.m. 
Opening Remarks
ASM and ESCMID Leadership
David Hooper
William Hope

Keynote Speaker
Moderator: Helen Boucher

8:15 a.m. – 8:45 a.m. 
Challenge of Antimicrobial Resistance in 2017
Yohei Doi
, University of Pittsburgh, Center for Care of Infectious Diseases

Regulatory Pathways for AMR and Technology Appraisal Process
Moderator: John Rex

8:45 a.m. - 9:15 a.m.
EMA Updates and Perspectives
Marco Cavaleri, European Medicines Agency

9:15 a.m. - 9:45 a.m.
FDA Updates and Perspectives
Sumathi Nambiar, Food and Drug Administration

9:45 a.m. - 10:15 a.m.
Technology Appraisal Process of New Antibiotics
Colm Leonard, Centre for Health Technology Evaluation, National Institute for Health and Care Excellence

10:15 a.m. - 10:45 a.m.
Coffee Break

Strategies and Experiences in Accelerated Drug Development Programs
Moderator: George Drusano

10:45 a.m. - 11:15 a.m.
David Melnick, Allergan

11:15 a.m. - 11:45 a.m.
Ian Friedland, Achaogen

11:45 a.m. - 12:15 p.m.
Michael Dudley, Rempex Pharmaceuticals

12:15 p.m. - 12:45 p.m.
Roundtable Discussion

12:45 p.m. - 1:45 p.m.

Challenges with Clinical Trial Design and Funding Issues
Moderator: Marco Cavaleri

1:45 p.m. - 2:15 p.m.
Pathogen-Specific Agent for Pseudomonas aeruginosa
Glenn Dale, Polyphor AG

2:15 p.m. - 2:45 p.m.
Targeting a Single Species: Acinetobacter baumannii
Robin Isaacs, Entasis Therapeutics

2:45 p.m. - 3:15 p.m.
Old Drug/New Formulation for Europe: Minocycline
Jeff Loutit, Rempex Pharmaceuticals

3:15 p.m. - 3:45 p.m. 
Old Drug/New Formulation for USA: Fosfomycin 
Evelyn J. Ellis-Grosse, Zavante Therapeutics

3:45 p.m. - 4:45 p.m.
Coffee Break / Poster Presentations 

AMR, Regulatory Science, and Drug Development
Moderators:  William Hope and Keith Rodvold

4:45 p.m. - 5:00 p.m.
Platform Research Presentation
Identification of a PptT Inhibitor that Kills M. tuberculosis and a Novel Mechanism of Resistance
Elaine Ballinger, Weill Cornell Medicine

5:00 p.m. - 5:15 p.m.
Platform Research Presentation
Inhibitors of Nucleotidyltransferase Superfamily Enzymes as a Novel Antibacterial Agent
Feng Cao, St. Louis VA Healthcare System

5:15 p.m. - 5:30 p.m.
Platform Research Presentation
Molecular Bases of Antibiotic Translocation Across Outer Membrane porinsBases of Antibiotic Translocation Across Outer Membrane porins
Muriel Masi, Aix-Marseille University

5:30 p.m. – 6:30 p.m.

Back to Wednesday's program 

Thursday, September 7, 2017


8:00 a.m. – 8:30 a.m.
Light Breakfast

Keynote Speaker
Moderator: Michael Sharland

8:30 a.m. - 9:00 a.m.
Global Priority List of AMR and 2017 Essential Medicine List
Nicola Magrini
, World Health Organization

Strategic Action Plans on Antibiotic Research and Development for AMR
Moderator: Helen Boucher

9:00 a.m. - 9:30 a.m.
Update on CARB-XED and DRIVE AB Final Conference
John Rex, F2G Ltd, CARB-X, Wellcome Trust, Advent Life Sciences

9:30 a.m. - 10:00 a.m. 
Strategic Priority for AMR
Tim Jinks
, Wellcome Trust

10:00 a.m. - 10:30 a.m. 
Coffee Break

Clinical Microbiology for a Development Program – Sponsored by CARB-XED, GARDP, ASM, and ESCMID
Moderator: Judith Steenbergen

10:30 a.m. - 11:00 a.m.
Groundwork for In vitro Activity, Indication, and IND
Erika Matuschek, ESCMID

11:00 a.m. - 11:30 a.m.
NDA Requirements: Clinical Trial Data, Surveillance, Breakpoints
Kevin Krause, Achaogen

11:30 a.m. - 12:00 p.m.
Making Antibacterial Susceptibility Available in Clinical Practice
Robin Patel, Mayo Clinic

12:00 p.m. - 12:30 p.m.
Roundtable: Pitfalls in Development

12:30 p.m. – 1:30 p.m.

PK-PD Dosing Issues in Special Patient Populations
Moderator: Alasdair MacGowan

1:30 p.m. - 2:00 p.m.
Critically Ill Patients versus Healthy Volunteers
Jason Roberts, The University of Queensland

2:00 p.m. - 2:30 p.m.
CLcr of 30-50 vs >120 mL/min: Dosing Issues or Special Populations?
Thomas Lodise, Albany College of Pharmacy and Health Sciences

2:30 p.m. - 3:00 p.m.
Neonates and Infants
Mike Sharland, St. George’s, University of London

3:00 p.m. - 3:30 p.m.
Pediatrics: At the Interface Between Pharmacometrics and Regulatory Science
Gilbert Burckart, Food and Drug Administration

3:30 p.m. - 4:30 p.m.
Coffee Break / Poster Presentations

Global Strategies, Microbiology, PK-PD, and Special Populations
Moderators:  William Hope and Keith Rodvold

4:30 p.m. - 4:45 p.m.
Platform Research Presentation
Pharmacokinetics and Comprehensive Analysis of Tissue Distribution of Eravacycline Following Intravenous Administration in Rabbits
Vidmantas Petraitis, Weill Cornell Medicine of Cornell University

4:45 p.m. - 5:00 p.m.
Platform Research Presentation
Relationship Between Gepotidacin (GSK1440944) Pharmacokinetics-Pharmacodynamics and Escherichia coli Resistance Amplification Prevention in a Hollow-Fiber Infection Model (HFIM)
Brian D. VanScoy, ICPD

5:00 p.m. - 5:15 p.m.
Platform Research Presentation
Synergistic Peptidomimetic-Antimicrobial Combinations to Combat Multidrug Resistant Gram-Negative Bacterial Infections
Kristin Baker, University of Copenhagen

5:45 p.m. – 7:15 p.m. 
Reception (extra fee)

Back to Thursday's program

Friday, September 8, 2017

7:30 a.m. – 8:00 a.m.
Light Breakfast

Keynote Speaker
Moderator: Edward Cox

8:00 a.m. - 8:30 a.m.
Finding New Therapeutic Agents: Triumphs and Tragedies
Heinz Moser, Novartis

Understand and Overcome Membrane Barriers of Gram-Negative Bacteria
Moderator: George Drusano

8:30 a.m. - 9:00 a.m.
Drug Penetration and the Multiple Target Hypothesis: Two Challenges to Antibacterial Discovery
Lynn Silver, LL Silver Consulting, LLC

9:00 a.m. - 9:30 a.m.
Porin Mediated Uptake
Ruben Tommasi, Entasis Therapeutics

9:30 a.m. - 10:00 a.m.
How Much Drug Gets to the Target?
Kyu Rhee, Weill Cornell Medical College

10:00 a.m. - 10:30 a.m.
Outer Membrane Permeabilizer
Aileen Rubio, Spero Therapeutics

10:30 a.m . - 11:00 a.m.
Coffee Break

11:00 a.m. - 11:15 a.m.
Conclusion and Closing of the Conference

11:15 a.m. - 12:00 p.m.
Open Planning Meeting for the 2018 Conference in Europe

Dr. Selma Stern was scheduled to present on “Global Union for Antibiotics Research and Development (GUARD)” at the 2017 ASM/ESCMID conference and unfortunately was unable to attend. Dr. Stern has however provided her study “Breaking through the Wall” for our reference.

Back to Friday's program 

For questions or comments, please email